PT  - JOURNAL ARTICLE
AU  - Jean Claude Reubi
AU  - Helmut R. Maecke
TI  - Peptide-Based Probes for Cancer Imaging
AID  - 10.2967/jnumed.108.053041
DP  - 2008 Nov 01
TA  - Journal of Nuclear Medicine
PG  - 1735--1738
VI  - 49
IP  - 11
4099  - http://jnm.snmjournals.org/content/49/11/1735.short
4100  - http://jnm.snmjournals.org/content/49/11/1735.full
SO  - J Nucl Med2008 Nov 01; 49
AB  - Receptors for regulatory peptides are overexpressed in a variety of human cancers. They represent the molecular basis for in vivo imaging with radiolabeled peptide probes. Somatostatin-derived tracers, designed to image the sst2-overexpressing neuroendocrine tumors, have enjoyed almost 2 decades of successful development and extensive clinical applications. More recent developments include second- and third-generation somatostatin analogs, with a broader receptor subtype profile or with antagonistic properties. Emerging tracers for other peptide receptors, including cholecystokinin/gastrin and GLP-1 analogs for neuroendocrine tumors, bombesin and neuropeptide-Y analogs for prostate or breast cancers, or Arg-Gly-Asp peptides for neoangiogenesis labeling, are also in current development. Application fields include both SPECT/CT and PET/CT.